159 related articles for article (PubMed ID: 21671362)
1. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Langholz B; Skolnik JM; Barrett JS; Renbarger J; Seibel NL; Zajicek A; Arndt CA
Pediatr Blood Cancer; 2011 Aug; 57(2):252-7. PubMed ID: 21671362
[TBL] [Abstract][Full Text] [Related]
2. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study.
Green DM; Norkool P; Breslow NE; Finklestein JZ; D'Angio GJ
J Clin Oncol; 1990 Sep; 8(9):1525-30. PubMed ID: 2167951
[TBL] [Abstract][Full Text] [Related]
3. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
[TBL] [Abstract][Full Text] [Related]
4. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the National Wilms' Tumor Study.
Green DM; Finklestein JZ; Norkool P; D'Angio GJ
Cancer; 1988 Jul; 62(2):270-3. PubMed ID: 2838151
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumour: adjuvant treatment with actinomycin D and vincristine.
Jenkin RD; Jeffs RD; Stephens CA; Sonley MJ
Can Med Assoc J; 1976 Jul; 115(2):136-40. PubMed ID: 179690
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
7. [Veno-occlusive disease of the liver and nephroblastoma in children (role of the vincristine-actinomycin combination?].
Chevallier B; Treluyer JM; Devictor D; Yaiche MC; Lagardère B
Ann Pediatr (Paris); 1988 Sep; 35(7):525-6. PubMed ID: 2460015
[No Abstract] [Full Text] [Related]
8. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor.
Tournade MF; Com-Nougué C; Voûte PA; Lemerle J; de Kraker J; Delemarre JF; Burgers M; Habrand JL; Moorman CG; Bürger D
J Clin Oncol; 1993 Jun; 11(6):1014-23. PubMed ID: 8388918
[TBL] [Abstract][Full Text] [Related]
9. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Moksness J; Finklestein JZ; D'Angio GJ
J Clin Oncol; 1994 Oct; 12(10):2132-7. PubMed ID: 7931484
[TBL] [Abstract][Full Text] [Related]
10. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
[TBL] [Abstract][Full Text] [Related]
11. Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group.
Feusner JH; Ritchey ML; Norkool PA; Takashima JR; Breslow NE; Green DM
Pediatr Blood Cancer; 2008 Feb; 50(2):242-5. PubMed ID: 17458877
[TBL] [Abstract][Full Text] [Related]
12. Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.
Altaf S; Enders F; Lyden E; Donaldson SS; Rodeberg D; Arndt C
J Pediatr Hematol Oncol; 2014 Nov; 36(8):599-604. PubMed ID: 24936741
[TBL] [Abstract][Full Text] [Related]
13. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract][Full Text] [Related]
14. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
15. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.
Pritchard J; Imeson J; Barnes J; Cotterill S; Gough D; Marsden HB; Morris-Jones P; Pearson D
J Clin Oncol; 1995 Jan; 13(1):124-33. PubMed ID: 7799012
[TBL] [Abstract][Full Text] [Related]
16. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
Arndt C; Hawkins D; Anderson JR; Breitfeld P; Womer R; Meyer W
J Clin Oncol; 2004 May; 22(10):1894-901. PubMed ID: 15143082
[TBL] [Abstract][Full Text] [Related]
17. Single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor. Preliminary results of a clinical trial. The Brazilian Wilms' Tumor Study Group.
de Camargo B; Franco EL
Cancer; 1991 Jun; 67(12):2990-6. PubMed ID: 1646068
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-related toxicity in infants treated according to the Second National Wilms' Tumor Study.
Morgan E; Baum E; Breslow N; Takashima J; D'Angio G
J Clin Oncol; 1988 Jan; 6(1):51-5. PubMed ID: 2826715
[TBL] [Abstract][Full Text] [Related]
19. Unexpected toxicity encountered in the National Wilms' Tumor Study.
D'Angio GJ
Cancer Treat Rep; 1987 Oct; 71(10):993. PubMed ID: 2820573
[No Abstract] [Full Text] [Related]
20. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
